PL3601296T3 - Pochodne 2-okso-tiazolowe jako inhibitory i związki a2a do stosowania w leczeniu nowotworów złośliwych - Google Patents
Pochodne 2-okso-tiazolowe jako inhibitory i związki a2a do stosowania w leczeniu nowotworów złośliwychInfo
- Publication number
- PL3601296T3 PL3601296T3 PL18716193.0T PL18716193T PL3601296T3 PL 3601296 T3 PL3601296 T3 PL 3601296T3 PL 18716193 T PL18716193 T PL 18716193T PL 3601296 T3 PL3601296 T3 PL 3601296T3
- Authority
- PL
- Poland
- Prior art keywords
- cancers
- oxo
- inhibitors
- compounds
- treatment
- Prior art date
Links
- CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical class OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D497/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17163781 | 2017-03-30 | ||
| US201762565281P | 2017-09-29 | 2017-09-29 | |
| EP17194084 | 2017-09-29 | ||
| ARP180100778A AR111200A1 (es) | 2017-03-30 | 2018-03-28 | Derivados de tiocarbamato como inhibidores de a2a y métodos para usar en el tratamiento de cánceres |
| PCT/EP2018/058301 WO2018178338A1 (en) | 2017-03-30 | 2018-03-30 | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3601296T3 true PL3601296T3 (pl) | 2022-10-10 |
Family
ID=61911575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18716193.0T PL3601296T3 (pl) | 2017-03-30 | 2018-03-30 | Pochodne 2-okso-tiazolowe jako inhibitory i związki a2a do stosowania w leczeniu nowotworów złośliwych |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10995101B2 (pl) |
| EP (2) | EP3601296B1 (pl) |
| JP (2) | JP7197558B2 (pl) |
| KR (2) | KR102640927B1 (pl) |
| CN (3) | CN115873022A (pl) |
| AU (1) | AU2018246355B2 (pl) |
| BR (1) | BR112019020421A8 (pl) |
| CA (1) | CA3058260A1 (pl) |
| DK (1) | DK3601296T3 (pl) |
| ES (1) | ES2926158T3 (pl) |
| HR (1) | HRP20221039T1 (pl) |
| HU (1) | HUE059990T2 (pl) |
| IL (2) | IL300149A (pl) |
| LT (1) | LT3601296T (pl) |
| MX (2) | MX393711B (pl) |
| PL (1) | PL3601296T3 (pl) |
| RS (1) | RS63557B1 (pl) |
| SI (1) | SI3601296T1 (pl) |
| TW (1) | TWI836960B (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115873022A (zh) * | 2017-03-30 | 2023-03-31 | 伊忒欧斯比利时股份公司 | 作为a2a抑制剂的2-氧代噻唑衍生物和用于治疗癌症的化合物 |
| JP2020527588A (ja) | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| BR112020000962A2 (pt) | 2017-07-18 | 2020-07-14 | Nuvation Bio Inc. | compostos de 1,8-naftiridinona e usos dos mesmos |
| MX2021002865A (es) * | 2018-09-11 | 2021-07-16 | iTeos Belgium SA | Derivados de tiocarbamato como inhibidores de a2a, composición farmacéutica de los mismos y combinaciones con agentes antineoplásicos. |
| US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| US11427594B2 (en) | 2018-09-27 | 2022-08-30 | iTeos Belgium SA | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers |
| CN113939291A (zh) | 2019-01-18 | 2022-01-14 | 诺维逊生物股份有限公司 | 1,8-萘啶酮化合物及其用途 |
| BR112021013936A2 (pt) | 2019-01-18 | 2021-09-21 | Nuvation Bio Inc. | Compostos heterocíclicos como antagonistas de adenosina |
| CN114539265B (zh) * | 2022-03-02 | 2023-07-21 | 中山大学 | 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6921825B2 (en) | 1998-09-16 | 2005-07-26 | King Pharmaceuticuals Research & Development, Inc. | Adenosine A3 receptor modulators |
| US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| SI1283839T1 (pl) * | 2000-05-26 | 2005-08-31 | Schering Corp | |
| US20080070932A1 (en) * | 2003-04-09 | 2008-03-20 | Chi Vu | Triazolo[ 1,5-A] Pyrimidines And Pyrazolo[ 1,5-A] Pyrimidines And Methods Of Making And Using The Same |
| KR20060135901A (ko) * | 2004-04-21 | 2006-12-29 | 쉐링 코포레이션 | 피라졸로-[4,3-ｅ]-1,2,4-트리아졸로-[1,5-ｃ]피리미딘아데노신 Ａ2ａ 수용체 길항제 |
| WO2007140181A2 (en) | 2006-05-26 | 2007-12-06 | King Pharmaceuticals Research And Development, Inc. | Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist |
| US7691869B2 (en) | 2007-03-30 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
| WO2009011897A1 (en) | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Combinations for the treatment of b-cell proliferative disorders |
| US20110237599A1 (en) | 2010-03-10 | 2011-09-29 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| JP5843869B2 (ja) | 2010-09-24 | 2016-01-13 | アドヴィナス・セラピューティックス・リミテッド | アデノシン受容体拮抗薬としての縮合三環化合物 |
| WO2012055015A1 (en) | 2010-10-26 | 2012-05-03 | Alberta Health Services | Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer |
| WO2012135084A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| TWI781136B (zh) | 2017-01-20 | 2022-10-21 | 美商阿克思生物科學有限公司 | 用於治療癌症相關病症之唑嘧啶 |
| CN115873022A (zh) * | 2017-03-30 | 2023-03-31 | 伊忒欧斯比利时股份公司 | 作为a2a抑制剂的2-氧代噻唑衍生物和用于治疗癌症的化合物 |
| WO2018178338A1 (en) | 2017-03-30 | 2018-10-04 | Iteos Therapeutics | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
| WO2019123482A1 (en) | 2017-12-19 | 2019-06-27 | Impetis Biosciences Ltd. | Pharmaceutical composition for the treatment of cancer |
| US11376255B2 (en) * | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| MX2021002865A (es) | 2018-09-11 | 2021-07-16 | iTeos Belgium SA | Derivados de tiocarbamato como inhibidores de a2a, composición farmacéutica de los mismos y combinaciones con agentes antineoplásicos. |
| US11427594B2 (en) | 2018-09-27 | 2022-08-30 | iTeos Belgium SA | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers |
| WO2020065036A1 (en) | 2018-09-27 | 2020-04-02 | Iteos Therapeutics S.A. | Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist |
-
2018
- 2018-03-30 CN CN202211706953.0A patent/CN115873022A/zh active Pending
- 2018-03-30 BR BR112019020421A patent/BR112019020421A8/pt active Search and Examination
- 2018-03-30 IL IL300149A patent/IL300149A/en unknown
- 2018-03-30 PL PL18716193.0T patent/PL3601296T3/pl unknown
- 2018-03-30 CA CA3058260A patent/CA3058260A1/en active Pending
- 2018-03-30 HU HUE18716193A patent/HUE059990T2/hu unknown
- 2018-03-30 HR HRP20221039TT patent/HRP20221039T1/hr unknown
- 2018-03-30 EP EP18716193.0A patent/EP3601296B1/en active Active
- 2018-03-30 MX MX2019011743A patent/MX393711B/es unknown
- 2018-03-30 KR KR1020197031322A patent/KR102640927B1/ko active Active
- 2018-03-30 JP JP2020503355A patent/JP7197558B2/ja active Active
- 2018-03-30 LT LTEPPCT/EP2018/058301T patent/LT3601296T/lt unknown
- 2018-03-30 SI SI201830747T patent/SI3601296T1/sl unknown
- 2018-03-30 TW TW112113401A patent/TWI836960B/zh active
- 2018-03-30 ES ES18716193T patent/ES2926158T3/es active Active
- 2018-03-30 AU AU2018246355A patent/AU2018246355B2/en active Active
- 2018-03-30 RS RS20220794A patent/RS63557B1/sr unknown
- 2018-03-30 CN CN202211658370.5A patent/CN115991679A/zh active Pending
- 2018-03-30 CN CN201880034926.9A patent/CN110678472B/zh active Active
- 2018-03-30 KR KR1020247005971A patent/KR20240027885A/ko active Pending
- 2018-03-30 DK DK18716193.0T patent/DK3601296T3/da active
- 2018-03-30 EP EP22165965.9A patent/EP4112623A1/en not_active Withdrawn
-
2019
- 2019-03-14 US US16/354,022 patent/US10995101B2/en active Active
- 2019-09-26 IL IL269710A patent/IL269710B2/en unknown
- 2019-09-30 MX MX2022005298A patent/MX2022005298A/es unknown
-
2020
- 2020-08-14 US US16/993,897 patent/US20210198281A1/en not_active Abandoned
-
2022
- 2022-09-21 US US17/949,595 patent/US20230159564A1/en not_active Abandoned
- 2022-12-15 JP JP2022199962A patent/JP2023027282A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256874B (en) | Immune checkpoint suppressors for use in the treatment of blood-borne cancers | |
| IL272948B1 (en) | enpp1 inhibitors and their use for cancer treatment | |
| LT3675854T (lt) | Piperidinilindolo dariniai, skirti c3 glomerulopatijai gydyti | |
| ZA201803742B (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| ZA201807810B (en) | Adenosine derivatives for use in the treatment of cancer | |
| IL258979B (en) | The use of pyrimidine and pyridine history in the treatment of cancer | |
| IL269710A (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers | |
| IL266198A (en) | Liposomal formulation for use in cancer treatment | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| IL247586A0 (en) | Use of Aribolin and mtor inhibitors as a combined treatment for cancer | |
| IL262863A (en) | Dihydrotestosterone and the history and promoters of dihydrotestosterone for cancer treatment | |
| ZA201705530B (en) | 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors | |
| PL3402468T3 (pl) | Inhibitory pi3k p-delta 110 do zastosowania w dostarczaniu wirusów w leczeniu nowotworu | |
| IL253933A0 (en) | History of pyrimidine use in the treatment of cancer | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| PT3601296T (pt) | Derivados de 2-oxo-tiazóis como inibidores de a2a e compostos para uso no tratamento de cancros | |
| HK40003303A (en) | Adenosine derivatives for use in the treatment of cancer | |
| HK40015947A (en) | Oxazole derivatives for use in the treatment of cancer | |
| HK40015946A (en) | Oxazole derivatives for use in the treatment of cancer |